President and CEO of Bluebird Bio Inc (NASDAQ:BLUE) Nick Leschly sold 117,500 shares of BLUE on 12/13/2017 at an average price of $184.08 a share. The total sale was $21.6 million.
bluebird bio Inc is a clinical-stage biotechnology company which develops gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. bluebird bio Inc has a market cap of $8.38 billion; its shares were traded at around $182.95 with and P/S ratio of 233.32.
CEO Recent Trades:
President and CEO Nick Leschly sold 117,500 shares of BLUE stock on 12/13/2017 at the average price of $184.08. The price of the stock has decreased by 0.61% since.
Directors and Officers Recent Trades:
Director Mark Vachon sold 7,000 shares of BLUE stock on 12/11/2017 at the average price of $216.64. The price of the stock has decreased by 15.55% since.and Strategy Officer Jeffrey T. Walsh sold 9,900 shares of BLUE stock on 12/11/2017 at the average price of $216.54. The price of the stock has decreased by 15.51% since.COO Susanna Gatti High sold 1,282 shares of BLUE stock on 12/01/2017 at the average price of $172.15. The price of the stock has increased by 6.27% since.Chief Scientific Officer Philip D Gregory sold 2,250 shares of BLUE stock on 12/01/2017 at the average price of $172.54. The price of the stock has increased by 6.03% since.Chief Medical Officer David Davidson sold 4,000 shares of BLUE stock on 12/01/2017 at the average price of $172.42. The price of the stock has increased by 6.11% since.
For the complete insider trading history of BLUE, click here
Top 5 Medical Stocks To Buy For 2019: Blue Capital Reinsurance Holdings Ltd.(BCRH)
- [By Shane Hupp]
Blue Capital Reinsurance (NYSE:BCRH) reached a new 52-week high and low during trading on Thursday . The company traded as low as $10.90 and last traded at $11.05, with a volume of 17133 shares trading hands. The stock had previously closed at $11.20.
- [By Joseph Griffin]
Here are some of the headlines that may have impacted Accern’s rankings:
Get Akari Therapeutics alerts:
Akari Therapeutics, Plc (AKTX) Analysts See $-1.00 EPS; HC INTERNATIONAL ORDINARY SHARES CA (HCINF … (mtastar.com) Trader’s Buzzers- Boxlight Corporation (NASDAQ:BOXL), Blue Capital Reinsurance Holdings Ltd. (NYSE:BCRH), Akari … (journalfinance.net) Akari Therapeutics (AKTX) Lifted to “Hold” at ValuEngine (americanbankingnews.com) Guillain-Barre Syndrome Market to reach value of US$ 708.6 Mn by 2025, Says TMRGlobal GuillainBarre Syndrome … (markets.businessinsider.com) Analysts See $-1.00 EPS for Akari Therapeutics, Plc (AKTX); Verastem (VSTM) SI Decreased By 7.78% (mtastar.com)
Several brokerages have commented on AKTX. ValuEngine upgraded Akari Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday. Canaccord Genuity cut their target price on Akari Therapeutics from $15.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday, March 29th. B. Riley began coverage on Akari Therapeutics in a research note on Thursday, February 8th. They issued a “neutral” rating and a $3.00 target price for the company. Finally, Zacks Investment Research downgraded Akari Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 16th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $4.63.
Top 5 Medical Stocks To Buy For 2019: Rayonier Advanced Materials Inc.(RYAM)
- [By Travis Hoium]
Shares of materials company Rayonier Advanced Materials Inc (NYSE:RYAM) jumped as much as 11.8% in trading Thursday after announcing a major acquisition. At 3:30 p.m. EDT, the shares were holding at a 10.6% gain on the day.
Top 5 Medical Stocks To Buy For 2019: Acacia Research Corporation(ACTG)
- [By Stephan Byrd]
ValuEngine lowered shares of Acacia Research (NASDAQ:ACTG) from a buy rating to a hold rating in a report published on Wednesday morning.
ACTG has been the topic of a number of other reports. Zacks Investment Research downgraded shares of Acacia Research from a buy rating to a hold rating in a report on Friday, March 23rd. TheStreet downgraded shares of Acacia Research from a c- rating to a d rating in a report on Friday, February 16th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the stock. The company presently has a consensus rating of Hold and an average price target of $5.67.
Top 5 Medical Stocks To Buy For 2019: P.T. Telekomunikasi Indonesia Tbk.(TLK)
- [By Lisa Levin]
Tuesday afternoon, the telecommunication services shares climbed 1.18 percent. Meanwhile, top gainers in the sector included Intelsat S.A. (NYSE: I), up 7 percent, and Telekomnks Indn Prsr Tbk Prshn Prsrn-ADR (NYSE: TLK), up 3 percent.
- [By Lisa Levin]
In trading on Wednesday, telecommunications services shares fell 0.45 percent. Meanwhile, top losers in the sector included Telekomunikasi Indones (Prsr)Tbk PT-ADR (NYSE: TLK), down 4 percent, and China Telecom Corporation Limited (ADR) (NYSE: CHA) down 2 percent.
Top 5 Medical Stocks To Buy For 2019: Avanir Pharmaceuticals Inc(AVNR)
- [By Paul Ausick]
Stocks on the move: Galena Biopharma Inc. (NASDAQ: GALE) is down 15.4% at $1.93 after pricing a secondary offering of 17.5 million units at $2.00. Safeway Inc. (NYSE: SWY) is up 6.1% at $28.21, after an analysts upgrade which sent shares to a new 52-week high of $28.88 earlier. Avanir Pharmaceuticals Inc. (NASDAQ: AVNR) is down 18.2% at $4.08.